FDA授予zanidatamab-hrii加速批准,用于既往接受过治疗、不可切除或转移性HER2阳性胆道癌
正文 · 中文译文
FDA加速批准zanidatamab-hrii用于既往接受过治疗、不可切除或转移性HER2阳性胆道癌 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2024年11月20日,美国食品药品监督管理局(FDA)加速批准zanidatamab-hrii(Ziihera,Jazz Pharmaceuticals, Inc.),一种靶向HER2的双特异性抗体,用于经FDA批准检测方法检出、既往接受过治疗、不可切除或转移性HER2阳性(IHC 3+)胆道癌(BTC)。 今日,FDA还批准VENTANA PATHWAY抗HER-2/neu(4B5)兔单克隆一抗(Ventana Medical Systems, Inc./Roche Diagnostics)作为伴随诊断器械,以帮助识别可能符合Ziihera治疗条件的BTC患者。 Ziihera的完整处方信息将发布在Drugs@FDA上。 有效性与安全性 有效性在HERIZON-BTC-01(NCT04466891)中进行了评估,该研究是一项开放标签、多中心、单臂试验,纳入62例不可切除或转移性HER2阳性(IHC3+)BTC患者。患者须在晚期疾病阶段至少接受过一种含吉西他滨的方案治疗。 主要疗效结局指标为独立中心审查根据RECIST v1.1确定的客观缓解率(ORR)和缓解持续时间(DOR)。ORR为52%(95% CI:39,65),中位DOR为14.9个月(95% CI:7.4,不可估计)。 处方信息包含胚胎-胎儿毒性的黑框警告。在接受zanidatamab-hrii治疗的患者中,至少20%报告的最常见不良反应为腹泻、输注相关反应、腹痛和疲乏。 zanidatamab-hrii的推荐剂量为20 mg/kg,每2周静脉输注一次,直至疾病进展或出现不可接受的毒性。 本审评使用了Assessment Aid,这是申请人自愿提交以促进FDA审评的文件。 加快审评程序 本申请获得了优先审评、突破性疗法认定和孤儿药认定。FDA加快审评程序在《行业指南:严重疾病药物和生物制品的加快审评程序》中有所描述。 医疗卫生专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需关于研究性肿瘤产品单患者IND的协助,医疗卫生专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X上关注肿瘤卓越中心:@FDAOncology。 内容截至日期: 2024年11月21日 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On November 20, 2024, the Food and Drug Administration granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. Today, the FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc./Roche Diagnostics) as a companion diagnostic device to aid in identifying patients with BTC who may be eligible for treatment with Ziihera. Full prescribing information for Ziihera will be posted on Drugs@FDA. Efficacy and Safety Efficacy was evaluated in HERIZON-BTC-01 (NCT04466891), an open-label multicenter, single-arm trial in 62 patients with unresectable or metastatic HER2-positive (IHC3+) BTC. Patients were required to have received at least one prior gemcitabine-containing regimen in the advanced disease setting. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as determined by an independent central review according to RECIST v1.1. ORR was 52% (95% CI: 39, 65) and median DOR was 14.9 months (95% CI: 7.4, not estimable). The prescribing information contains a boxed warning for embryo-fetal toxicity. The most common adverse reactions reported in at least 20% of patients who received zanidatamab-hrii were diarrhea, infusion-related reactions, abdominal pain, and fatigue. The recommended zanidatamab-hrii dose is 20 mg/kg administered as an intravenous infusion once every 2 weeks until progression or unacceptable toxicity. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. Expedited Programs This application was granted priority review, breakthrough therapy designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X: @FDAOncology. Content current as of: 11/21/2024 Regulated Product(s) Drugs Oncology